The Insulin-like Growth Factor 1 Receptor (IGF1) is also known as CD221, JTK13. and is a transmembrane receptor that is activated by IGF-1 and by the related growth factor IGF-2. It belongs to the large class of tyrosine kinase receptors. This receptor mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin. IGF1R is make up of two alpha subunits and two beta subunits ,the Both the α and β subunits are synthesized from a single mRNA precursor. The precursor is then glycosylated, proteolytically cleaved, and crosslinked by cysteine bonds to form a functional transmembrane αβ chain.The α chains are located extracellularly while the β subunit spans the membrane and are responsible for intracellular signal transduction upon ligand stimulation. IGF1R have a binding site for ATP, which is used to provide the phosphates for autophosphorylation. There is a 60% homology between IGF1R and the insulin receptor. In response to ligand binding, the α chains induce the tyrosine autophosphorylation of the β chains. This event triggers a cascade of intracellular signaling that, while somewhat cell type specific, often promotes cell survival and cell proliferation.
Breast cancer, Solid tumours, Soft tissue sarcoma, Sarcoma, Hepatocellular carcinoma (HCC), Head and neck cancer, Rhabdomyosarcoma, Thymic tumor, Neuroendocrine tumors (NET), Non small cell lung cancer (NSCLC), Prostate cancer, Esophageal adenocarcinoma, Colorectal cancer, Pancreatic cancer
Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Prostate cancer, Gynaecological cancer, Gastrointestinal cancer, Breast cancer, Solid tumours, Multiple myeloma (MM), Colorectal cancer, Sarcoma, Rheumatoid arthritis (RA)